Genetics Generation Advancement Corp (4160) Fair Value & Analysis
Healthcare · TW · Market cap 1.1B TWD
Fair value as of: Jul 23, 2026
From 16 valuation models · updated 18 days ago
Share price −3.0% over the past month.
Below-average quality, and screening another 66% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (17.02 TWD). The favourable scenario is already priced in.
- Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 19.21 TWD – 134.19 TWD · fair‑value band 10.21 TWD – 17.02 TWD · the 40.40 TWD price screens above the 13.61 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.
Analysis
Genetics Generation Advancement Corp (4160) currently trades at 40.40 TWD, while our model-based Fair Value estimate is 13.61 TWD, implying the stock looks roughly 66.3% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Genetics Generation Advancement Corp generated revenue of 609M TWD at a net margin of 2.3%. Revenue grew 4.2% year over year. It earns a return on equity of 2.6%. Net debt stands at 5.2M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 10.21 TWD (bear case) to 17.02 TWD (bull case); at 40.40 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -66%, 4160 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Dividend Discount (19.40 TWD) versus Earnings-Based (5.91 TWD). Highest evidence: Residual Income (76).
Notify me when 4160 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Genetics Generation Advancement Corp. provides genetic testing, molecular and science diagnostics, biotechnology, precision health, and digital innovation services in Taiwan.
Full company description
Genetics Generation Advancement Corp. provides genetic testing, molecular and science diagnostics, biotechnology, precision health, and digital innovation services in Taiwan. The company offers testing services, including pre-implantation, prenatal, newborn medical examination, health management, reproductive medicine testing, obstetrics and gynecology testing, and neonatology and pediatrics testing, as well as gastroenterology, hepatology, oncology, and medical research services. It also provides bioinformatic, materials sciences, research and development management, enterprise quality management, process production operation, and e-submission products. The company was formerly known as Genesis Genetics Asia Corp. and changed its name to Genetics Generation Advancement Corp. in February 2016. Genetics Generation Advancement Corp. was founded in 2008 and is based in Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Genetics Generation Advancement Corp reported revenue of 603M TWD in FY2025 versus 520M TWD in FY2021, a compound +3.8%/yr. Reported net income was 21.4M TWD in FY2025, compounding +28.5%/yr from FY2021.
4160 screens 66% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Genetics Generation Advancement Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Genetics Generation Advancement Corp (4160) overvalued or undervalued?
What is the fair value of 4160?
What is the quality score of 4160?
What is the revenue of Genetics Generation Advancement Corp (4160)?
What is the net profit margin of 4160?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Genetics Generation Advancement Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.